Protection from Doxorubicin-Induced Cardiomyopathy Using the Modified Anthracycline N-Benzyladriamycin-14-valerate (AD 198)
- 28 July 2010
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 335 (1), 223-230
- https://doi.org/10.1124/jpet.110.167965
Abstract
The anthracycline doxorubicin (Dox) is an effective antitumor agent. However, its use is limited because of its toxicity in the heart. N-Benzyladriamycin-14-valerate (AD 198) is a modified anthracycline with antitumor efficacy similar to that of Dox, but with significantly less cardiotoxicity and potentially cardioprotective elements. In the present study, we investigated the possibility of in vivo protective effects of low-dose AD 198 against Dox-induced cardiomyopathy. To do this, rats were divided into four groups: vehicle, Dox (20 mg/kg; single injection day 1), AD 198 (0.3 mg/kg per injection; injections on days 1, 2, and 3), or a combination treatment of Dox + AD 198. Seventy-two hours after beginning treatment, hearts from the Dox group had decreased phosphorylation of AMP kinase and troponin I and reduced poly(ADP-ribose) polymerase, β-tubulin, and serum albumin expression. Dox also increased the phosphorylation of phospholamban and expression of inducible nitric-oxide synthase in hearts. Each of these Dox-induced molecular changes was attenuated in the Dox + AD 198 group. In addition, excised hearts from rats treated with Dox had a 25% decrease in left ventricular developed pressure (LVDP) and a higher than normal increase in LVDP when perfused with a high extracellular Ca2+ solution. The Dox-induced decrease in baseline LVDP and hyper-responsiveness to [Ca2+] was not observed in hearts from the Dox + AD 198 group. Thus Dox, with well established and efficient antitumor protocols, in combination with low levels of AD 198, to counter anthracycline cardiotoxicity, may be a promising next step in chemotherapy.Keywords
This publication has 37 references indexed in Scilit:
- Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardiumJCI Insight, 2010
- Tubulin polymerization modifies cardiac sodium channel expression and gatingCardiovascular Research, 2009
- Axial Stretch of Rat Single Ventricular Cardiomyocytes Causes an Acute and Transient Increase in Ca 2+ Spark RateCirculation Research, 2009
- AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic diseaseClinical Science, 2009
- Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin PathwayCell Metabolism, 2009
- N-Benzyladriamycin-14-valerate (AD 198): A Non-Cardiotoxic Anthracycline That Is Cardioprotective through PKC-ϵ ActivationJournal of Pharmacology and Experimental Therapeutics, 2007
- The late phase of preconditioning and its natural clinical application—gene therapyHeart Failure Reviews, 2007
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Circumvention of Nuclear Factor κB-Induced Chemoresistance by Cytoplasmic-Targeted AnthracyclinesMolecular Pharmacology, 2004
- Dexrazoxane pre‐treatment protects skinned rat cardiac trabeculae against delayed doxorubicin‐induced impairment of crossbridge kineticsBritish Journal of Pharmacology, 2002